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Abstract
The complement anaphylatoxin C5a has a pathogenetic role in endotoxin-induced lung inflammatory injury by regulating
phagocytic cell migration and activation. Endotoxin and C5a activate the enzyme sphingosine kinase (Sphk) 1 to generate
the signaling lipid sphingosine-1-phosphate (S1P), a critical regulator of phagocyte function. We assessed the function of
Sphk1 and S1P in experimental lung inflammatory injury and determined their roles in anaphylatoxin receptor signaling and
on the expression of the two C5a receptors, C5aR (CD88) and C5L2, on phagocytes. We report that Sphk1 gene deficient
(Sphk1
2/2) mice had augmented lung inflammatory response to endotoxin compared to wild type mice. Sphk1 was
required for C5a-mediated reduction in cytokine and chemokine production by macrophages. Moreover, neutrophils from
Sphk1
2/2 mice failed to upregulate the anaphylatoxin receptor C5L2 in response to LPS. Exogenous S1P restored C5L2 cell
surface expression of Sphk1
2/2 mouse neutrophils to wild type levels but had no effect on cell surface expression of the
other anaphylatoxin receptor, CD88. These results provide the first genetic evidence of the crucial role of Sphk1 in
regulating the balance between expression of CD88 and C5L2 in phagocytes. S1P-mediated up-regulation of C5L2 is a novel
therapeutic target for mitigating endotoxin-induced lung inflammatory injury.
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Introduction
Phagocytic cells, macrophages and polymorphonuclear neutro-
phils (PMNs) from septic patients express inordinate amount of the
enzyme sphingosine kinase 1 (Sphk1) compared to macrophages
and PMNs from control subjects [1]. Sphk1 phosphorylates
sphingosine to form sphingosine-1-phosphate (S1P). S1P in turn
signals through heptahelical G-protein-coupled receptors ex-
pressed in immune and vascular endothelial cells [2–5]. Most
cells constitutively express Sphk1, but Sphk1 expression is strongly
up-regulated by bacteria and lipopolysaccharide (LPS) [1]. S1P
has been reported to reduce neutrophilic inflammation [6–10]. In
a rat model of acute lung injury, PMN sequestration, production
of pro-inflammatory cytokines, NFkB activation, lung capillary
leakage, and lung myeloperoxidase (MPO) activity were all
reduced by administration of S1P [10].
The physiological concentration in plasma and tissue of S1P is
maintained by S1P generation from hematopoietic sources
[11,12]. Genetic deletion of Sphk1 reduces S1P concentrations
but is not lethal [13]. However, deletion of both Sphk1 and Sphk2
results in embryos with severe deficiency of S1P generation and
lethality in mid-gestation [14]. Tissue concentration of S1P is
normally low compared with lymph and blood [5]. Tissue
concentrations of S1P are low compared with lymph and blood.
This gradient in S1P concentration between blood and tissues
contributes to trans-endothelial immune cells trafficking, differen-
tiation, and function [15–17]. For example, low concentration of
S1P promotes inflammatory cell chemotaxis, whereas high
concentration is inhibitory [18,19] Etiologic agents and mediators
of sepsis, including LPS, TNF-a, and complement anaphylatoxin
C5a activate Sphk1 in PMNs and macrophages [20–23]. The
generation of C5a mediates its effects through the heptahelical
receptors CD88 (C5aR) and the more recently described C5L2,
both of which are expressed on myeloid and non-myeloid cells
[24,25]. In a mouse model of acute lung injury, genetic deletion of
C5L2 significantly aggravated the disease [26], and increased
lethality in response to LPS challenge [27]. The genetic deletion of
CD88 (C5aR) protected mice from acute lung injury [28]. These
results suggest opposing roles for the two known C5a receptors in
the pathogenesis of lung inflammation, a protective one for C5L2
and a detrimental one for CD88.
Because the mechanisms by which Sphk1 activation and S1P
generation reduce neutrophilic inflammation are not well
understood, we investigated the possible role of Sphk/S1P
signaling axis in regulating the balance between C5L2 and
CD88 and how this shift in balance might influence LPS-induced
neutrophilic lung inflammation in mice. Our results show that
Sphk1 is required to maintain S1P plasma concentration in
endotoxemic mice and reveal the essential link between Sphk1 and
up-regulation of C5L2. We observed that Sphk1-induced up-
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30742regulation of C5L2 is a critical factor preventing endotoxin-
induced lung inflammatory injury.
Results
Absence of Sphk1 intensifies lung inflammation and
increases lethality in endotoxin-induced sepsis in mice
Macrophages and neutrophils are hyper-activated in sepsis
leading to production of cytokines and chemokines that cause
inflammation [29]. LPS activates Sphk1 [21] and Sphk1 protein
expression is up-regulated in macrophages and neutrophils from
patients with severe sepsis [1]. In mice lacking Sphk1 (Sphk1
2/2),
lung tissue MPO activity, a measure of neutrophilic inflammation,
is significantly increased in naı ¨ve, non-LPS-challenged mice
compared to Sphk1
+/+ control mice (Fig. 1A). Administration of
a sublethal dose of LPS i.p. caused significantly greater MPO
activity in Sphk1
2/2 mice than in Sphk1
+/+ controls at 1 h and
3 h after LPS injection (Fig. 1A). Sphk1
2/2 mice have PMNs in
blood and bone marrow at numbers and percentages comparable
to Sphk1
+/+ controls (not shown). These data indicate exacerbated
inflammatory immune response in the Sphk1
2/2 mice in response
to LPS. Measurements of plasma cytokines tumor necrosis factor
(TNF)-a, interleukin (IL)-6, IL-1b and keratinocyte derived
chemokine (KC) showed augmented inflammatory response to
LPS. At 1 h after i.p. LPS administration, plasma concentrations
of TNF-a, IL-6, IL-1b, and KC were significantly greater in
Sphk1
2/2 than in Sphk1
+/+ mice (Figure 1B). In lung tissue lysate,
we found that KC and IL-6 concentrations were basally elevated
(Fig. 1C) consistent with the constitutive neutrophilic lung
inflammation seen in Sphk1
2/2 mice (see Fig. 1A). Moreover,
after LPS challenge, TNF-a, IL-6, and KC concentrations were
significantly greater in lungs from Sphk1
2/2 mice than from
Sphk1
+/+ littermate controls (Fig. 1C).
As observed previously [30], Sphk1
2/2 mice were significantly
more sensitive to lethal LPS doses (Fig. 1D). A single dose of
20 mg/kg LPS that was lethal for 40% of Sphk1
+/+ mice (LD40)
was lethal for 80% of Sphk1
2/2 mice (Fig. 1D). Others have
reported that a wild-type LD90 dose of LPS is lethal for only 25%
of Sphk1
2/2 mice [31]. Thus, we tested the possibility that, when
compared to a LD40 dose, Sphk1 function is different when a LD90
dose of LPS is used. We found that Sphk1
2/2 mice showed
significantly accelerated lethality to a single dose of 30 mg/kg LPS
that is lethal for 90% of Sphk1
+/+ controls (Fig. 1E). These data
show that Sphk1 is not required for induction of lethality in severe
endotoxemia. Sphk1, however, clearly counteracts inflammation
and lethality in mice challenged with LPS.
Pharmacological inhibition of Sphk1 enzymatic activity has
been reported as beneficial in mouse sepsis models [1]. Therefore,
we measured the product of Sphk1 enzymatic activity, S1P, in
plasma and lung tissue. Consistent with an earlier report [13], we
found that the plasma S1P concentration was significantly reduced
in naı ¨ve Sphk1
2/2 mice compared to Sphk1
+/+ controls (Fig. 2A).
After LPS challenge, Sphk1
+/+ mice maintained plasma S1P
concentrations comparable to non-challenged Sphk1
+/+ mice
(Fig. 2A). Sphk1
2/2 mice, however, failed to maintain their
already significantly reduced S1P concentrations. After LPS
challenge, S1P concentrations dropped significantly below the
plasma concentration of non-challenged Sphk1
2/2 littermate
controls (Fig. 2A). Lung tissue concentration did not change
significantly in either Sphk1
+/+ or Sphk1
2/2 mice (Fig. 2B). Thus,
Sphk1 is required for the S1P gradient between lung plasma and
tissue in LPS-induced experimental sepsis. The constitutive low
plasma S1P concentration, and the significantly lower S1P
concentration in experimental endotoxemia, might explain the
PMN lung inflammation and the exacerbated lung inflammatory
response to LPS seen in Sphk1
2/2 mice.
C5a-induced reduction in cytokine and chemokine
production depends on Sphk1
The complement-derived anaphylatoxin C5a can activate
Sphks in phagocytes [20,23]. C5a is deleterious in sepsis
presumably due to its excessive production [32,33]. We measured
plasma and lung tissue C5a concentrations in Sphk1
+/+ and
Sphk1
2/2 mice before and after challenge with LPS. We found no
significant increase in C5a concentrations after challenge with LPS
(Fig. 2C, D) and genetic deletion of Sphk1 had no effect on C5a
concentrations in endotoxemia (Fig. 2C, D). Thus, we surmised
that relative expression of the known C5a anaphylatoxin receptors
CD88 and C5L2 in inflammatory cells [26,27,34] may determine
the effects of C5a. It has been shown in mice lacking C5L2 that
LPS-induced septic shock is augmented [27], a result comparable
to that seen Sphk1
2/2 mice (see Fig. 1). Therefore, we analyzed the
cell surface expression of the two C5a receptors CD88 and C5L2
in neutrophils from Sphk1
+/+ or Sphk1
2/2 mice. We found that
Sphk1
2/2 mice had greatly reduced proportions of C5L2
+
circulating neutrophils and peritoneal macrophages when com-
pared to Sphk1
+/+ controls (Fig. 3A). PMNs and macrophages from
Sphk1
2/2 mice had significantly reduced C5L2 cell surface
expression compared to Sphk1
+/+ controls (Fig. 3B). CD88
expression, however, was comparable between genotypes
(Fig. 3A, B). Importantly, total C5L2 expression, as assessed by
fixing and permeabilizing cells before staining with specific Ab to
C5L2, was comparable in neutrophils and macrophages from
Sphk1
+/+ or Sphk1
2/2 mice (Fig. 3C) indicating that differences in
cell surface expression were not due to differences in total C5L2
protein concentration. PMNs isolated from peripheral blood of
Sphk1
+/+ mice had significantly up-regulated C5L2 cell surface
expression in response to LPS, whereas PMNs from Sphk1
2/2
mice failed to up-regulate C5L2 (Fig. 3D). CD88 cell surface
expression did not change significantly in response to LPS and
there was no difference between the genotypes (Fig. 3D). Next to
address a potential role of S1P in regulating C5a anaphylatoxin
receptor cell surface expression on PMNs, we added S1P to
PMNs. S1P restored cell surface expression of C5L2 on PMNs
isolated from peripheral blood of Sphk1
2/2 mice to the wild type
level (Fig. 3E), demonstrating a direct link between S1P and C5L2
cell surface expression.
C5a suppresses TNF-a production by LPS-stimulated human
PMNs [35]. To address the effects of C5a on phagocytes lacking
Sphk1, we stimulated mouse bone marrow derived macrophages
(BMDMs) with LPS in the presence or absence of C5a (Fig. 4A–
C). BMDMs from Sphk1
+/+ mice produced significantly greater
TNF-a and IL-6 than BMDMs from Sphk1
2/2 mice (Fig. 4A, B),
the opposite phenotype from that seen in vivo (see Fig. 1B). KC
concentrations were similar in both genotypes (Fig. 4C). C5a
significantly reduced LPS-induced TNF-a, IL-6, and KC
production by BMDMs from Sphk1
+/+ mice (Fig. 4A–C). In
BMDMs from Sphk1
2/2 mice, however, C5a co-stimulation did
not reduce TNF-a, IL-6, and KC production in response to LPS
(Fig. 4A–C). Stimulation with C5a alone did not induce any
detectable cytokine or chemokine production in cells of either
genotype (Fig. 4A–C). It should be noted that there was no
difference in proliferation or cell death in BMDMs from Sphk1
+/+
or Sphk1
2/2 mice in response to LPS or C5a stimulation (data not
shown).
C5a-induced downregulation of cytokine production is mediat-
ed in part by extracellular signal-regulated kinase (ERK) [36] and
ERK phosphorylation is known to a key downstream event
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response to C5a stimulation is dependent on C5L2 expression on
macrophages [27]. Thus, we stimulated BMDMs with C5a to
assess ERK activation. C5a strongly enhanced ERK1/2 phos-
phorylation in BMDMs derived from Sphk1
+/+ mice (Fig. 4D). By
contrast, C5a had little effect on ERK1/2 phosphorylation in
BMDMs derived from Sphk1
2/2 mice (Fig. 4D). LPS-induced
ERK1/2 phosphorylation, and ERK1/2 phosphorylation in
response to LPS plus C5a stimulation was normal in BMDMs
derived from Sphk1
2/2 mice (Fig. 4D). Thus, Sphk1 is required for
C5a induced C5L2-dependent activation of ERK1/2. These data
link Sphk1 activity to the complement anaphylatoxin C5a and the
anaphylatoxin receptor C5L2, and provide a novel mechanism by
which S1P counteracts endotoxin-induced inflammation (Fig. 4E).
Discussion
Here we have identified the critical role of Sphk1 in mediating
the expression of the C5a receptor C5L2 in phagocytes and
thereby in dampening the inflammatory response to LPS.
Sphk1
2/2 mice have an 80% increase of TNF-a in their plasma,
and a 100% increase in the PMN-attracting chemokine KC in
Figure 1. Genetic deletion of Sphk1 amplifies lung inflammation and lethality in mice. (A) Lung MPO activity. Sphk1
+/+ or Sphk1
2/2 (n=10
per time point of each genotype) mice were given LPS i.p. (0.5 mg/kg) and lungs were removed at the indicated times. Error bars represent s.d.
*p,0.01 by Student’s t-test. (B, C) Increased LPS-induced cytokine and chemokine production. TNF-a, IL-6, IL-1b, and KC were measured in plasma
(B) and TNF-a, IL-6 and KC in lung tissue lysates (C) from Sphk1
+/+ or Sphk1
2/2 mice, 1 h after i.p. LPS or saline injection. Error bars represent s.d.
*p,0.05 by Student’s t-test; n=5 for each genotype. (D) Increased LPS-induced lethality. Sphk1
+/+ or Sphk1
2/2 mice (n=10/genotype, representative
of three independent experiments) were given LPS i.p. (E) Increased LPS-induced lethality. Sphk1
+/+ or Sphk1
2/2 mice (n=10/genotype,
representative of three independent experiments) were given LPS i.p. Differences in mortality were assessed by log-rank test (p,0.05). UD,
undetected.
doi:10.1371/journal.pone.0030742.g001
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the deletion of Sphk1 in mice reduced significantly the lethality in
LPS-induced sepsis.
It is not clear whether the function of Sphk1 changes from
protective to detrimental when lethality is induced in half of a
cohort of mice instead of in 90% of a cohort of mice. Others have
reported that a low dose of LPS, which induces lethality in 50% of
wild type mice, produced similar lethality in 50% of Sphk1 gene
deficient mice. A higher dose of LPS, however, which induces
lethality in 90% of wild type mice, caused lethality in only 25% of
Sphk1
2/2 mice [31]. We found that the presence of Sphk1 was
always beneficial for mice challenged with endotoxin. Sphk1 was
anti-inflammatory when sublethal doses of LPS are used, and it
invariably attenuated and delayed lethality when lethal dose of
LPS are used.
The function of the anaphylatoxin receptor C5L2 is still not
fully defined [39]. C5L2 plays an important role in various models
of sepsis [26,27,34,40–42]. Our data suggest that C5a anaphyl-
atoxin signaling in mice is not regulated by the abundance of C5a,
because plasma and lung tissue C5a concentration did not change
during endotoxin-induced inflammation. We showed that cell
surface expression of the anaphylatoxin receptor C5L2 on
phagocytes depends critically on Sphk1 in response to LPS
challenge. The expression of the anaphylatoxin receptor CD88 in
parenchymal cells is up-regulated in experimental sepsis [32], a
pathogenetic mechanism that contributes to septic shock and
multi-organ failure [34]. Increased C5L2 expression on inflam-
matory cell surface induced by Sphk1, in contrast, appears to be
beneficial in mouse endotoxemia [27]. It is noteworthy that in
septic patients, the PMN cell surface expression of C5L2 decreases
with the severity of the clinical syndrome [40].
While the complement anaphylatoxin C5 is dispensable for the
development of severe sepsis that follows experimental polymicro-
bial infection [43], the receptors for its activation product, C5a,
CD88 and C5L2, are not. In mice, both CD88 and C5L2
contribute to the pathogenesis of polymicrobial sepsis [34]. In
contrast, in the more reductionist model used here, endotoxemia,
C5L2 signaling is beneficial, via C5a-induced downregulation of
cytokine production that is mediated, in part, by ERK activation
[36–38]. ERK activation in response to C5a, a response that is
Figure 2. Sphingosine-1-phosphate (S1P) and anaphylatoxin C5a concentrations in plasma and lung tissue. S1P concentrations in
plasma (A) or lung tissue lysate (B) or C5a concentrations in plasma (C) or lung tissue lysates (D) from Sphk1
+/+ or Sphk1
2/2 mice were determined
before or after i.p. LPS challenge (0.5 mg/kg), using the LC-MS/MS (46) or ELISA techniques. Error bars represent s.d. *p,0.005, **p,0.001, by
Student’s t-test. No significant differences in (B, C, D). n=10 for each genotype and time point.
doi:10.1371/journal.pone.0030742.g002
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ERK activation in response to LPS, however, occurs completely
normal in BMDMs from Sphk1 mice.
The phenotype of Sphk1
2/2 mice evident in the present study is
at odds with the phenotype of wild type mice treated with drugs to
inhibit Sphk1 activity or to diminish its expression [1]. There was
Figure 3. Sphk1 regulates cell surface expression of anaphylatoxin receptor C5L2. (A) in vivo cell surface expression of anaphylatoxin
receptors CD88 and C5L2 in circulating Gr1
+ neutrophils and F4/80
+ peritoneal macrophages from Sphk1
+/+ or Sphk1
2/2 mice was determined by
flow cytometry. The percentage of C5L2
+CD88
+ cells is shown. There is a significant reduction of C5L2
+ cells in Sphk1
2/2 mice. (B) Bar graph depicts
the mean fluorescence intensity (MFI 6 s.d.) of C5l2 or CD88 cell surface expression of cells from five mice per genotype. (C) Total C5L2 expression
(MFI) assessed by fixing and permeabilizing cells before staining with specific Ab to C5L2. Cell surface expression only, on non-permeabilized cells, is
shown for comparison. Representative histograms of C5L2 expression by circulating neutrophils and peritoneal macrophages from Sphk1
+/+ or
Sphk1
2/2 mice are shown. (D) Percentage change of anaphylatoxin receptors CD88 and C5L2 neutrophil cell surface expression after in vitro
stimulation with LPS (1 mg/ml) for 1 h compared to non-stimulated controls. (E) Exogenous S1P (250 nM) restores C5L2 cell surface expression of
Sphk1
2/2 PMNs to the level of Sphk1
+/+ PMNs. Error bars represent s.d. *p,0.05 by Student’s t-test. Representative of at least 3 independent
experiments with similar results. n.s., not significant.
doi:10.1371/journal.pone.0030742.g003
Sphingosine Kinase 1 Mediates C5L2
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30742no defect in NFkB activation in cells from Sphk1
2/2 mice
[21,30,44] whereas mice treated with an Sphk1 inhibitor had a
profound defect in NFkB activation [1]. Astonishingly, despite this
marked inhibition of NFkB transcriptional activity, there was no
defect in clearing polymicrobial infection in mice treated with
Sphk1 inhibitor [1]. Adaptive functional redundancy has been
suggested to explain the phenotype of Sphk1
2/2 mice. For the
Sphk1 function uncovered here, the maintenance of S1P plasma
levels in endotoxemia, no adaptive compensation appears to have
occurred.
It remains unclear how increased expression of the Sphk1
protein or increased Sphk activity in patients’ phagocytes
Figure 4. Anaphylatoxin C5a-mediated reduction in cytokine and chemokine production depends on Sphk1. BMDMs from Sphk1
+/+ or
Sphk1
2/2 mice were stimulated with LPS (500 ng/ml), with LPS concomitant with C5a (1 nM), or without C5a. Tissue culture supernatants were
harvested 2 h (TNF-a) or 8 h (IL-6 and KC) after the addition of stimuli. (A) TNF-a;( B); IL-6; (C) KC. Error bars represent s.d. *p,0.05 by Student’s t-test;
n=5 for each genotype; representative for at least three independent experiments. (D) Reduced C5a-induced ERK1/2 and activation. BMDMs from
Sphk1
+/+ or Sphk1
2/2 mice were stimulated with C5a (10 nM), LPS (500 ng/ml), LPS and C5a, or saline for 5 min. Cell lysates were processed for
immunoblotting with indicated antibodies. Representative of 3 independent experiments showing similar results. UD, undetected. (E) Model:
Reduction of inflammatory cytokine production by phagocytes stimulated with C5a requires Sphk1. The model links Sphk1 activity to the cell surface
expression of the anaphylatoxin receptor C5L2. LPS, C5a and inflammatory cytokines activate Sphk1 which is required to maintain S1P during
inflammation. S1P regulates C5L2 cell surface expression on phagocytes. C5a, via C5L2 expressed on the cell surface, reduces neutrophil inflammation
and inflammatory cytokine production by macrophages.
doi:10.1371/journal.pone.0030742.g004
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tion. Previous results point to increased Sphk1 protein expression
as required to promote inflammation in sepsis or as a
compensatory mechanism to curb inflammation. Our results favor
the latter protective anti-inflammatory role of Sphk1. Based on our
data, we attribute this function of Sphk1 to its essential role
inducing C5L2 expression in phagocytic cells and thereby
dampening C5a signaling and mitigating the lung inflammatory
response to endotoxin.
Materials and Methods
Ethics Statement
Mice were bred and maintained according to the guidelines and
with the approval of the University of Illinois animal care
committee (PHS Animal Welfare Assurance number A3460-01).
Mice
Mice were bred and maintained under specific pathogen-free
conditions at the University of Illinois animal facility. Sphk1
2/2
mice, as described [13], were backcrossed into a C57BL/6
background for 9 generations. Sphk1
+/+ and Sphk1
2/2 mice used
for all experiments were maintained in F9. For all experiments, 7–
14 wk old mice were used.
Induction of inflammatory lung injury and lethality
Mice received a single low dose (0.5 mg/kg) of LPS (E. coli
0111:B4, InvivoGen) intraperitoneally. For survival studies, mice
were injected intraperitoneally with a single dose of LPS (E. coli
0111:B4, InvivoGen), 20 mg/kg (LD40) or 30 mg/kg (LD90), and
monitored twice daily for 6 days.
Myeloperoxidase (MPO) assay
Lungs were perfused with PBS to remove all blood. Lungs were
weighed and frozen and stored at 280uC for no more than 1 wk
before MPO assay was performed. MPO activity was measured as
described [45].
S1P and C5a measurements
Lungs were perfused with PBS to remove all blood, frozen in
liquid nitrogen and processed for LC-MS/MS S1P determination
as described [46]. Exogenous S1P (Sigma) (250 nM) was added to
freshly isolated PMNs maintained in HBSS buffer containing
0.1% BSA and cells were processed for flow cytometry 1 h after
stimulation. For the C5a ELISA, purified rat anti-mouse C5a (BD
Pharmingen, 558027) was used as capturing Ab and rat
biotinylated anti-mouse C5a (BD Pharmingen, 558028) was used
as detection Ab and a standurd curve for C5a protein measurment
was established using mouse recombinant C5a (R&D Systems) (see
Figure S1).
Isolation of bone marrow-derived macrophages (BMDM)
BMDM from Sphk1
+/+ or Sphk1
2/2 mice were obtained and
differentiated as described [47]. BMDM were cultured as
described [45]. BMDM were placed into 12 well tissue culture
plates (1.5610
6 cells/well) in IDMD plus 10% heat inactivated
FBS. Cells were stimulated with LPS (500 ng/ml) in the presence
or absence of mouse recombinant C5a (R&D Systems) (1 nM).
Cytokine and chemokine concentration measurements
Tissue culture supernatants as well as sera were analyzed for the
presence of IL-6, TNF-a, IL-1b, and KC, using the Bio-Plex
Multiplex Cytokine Assay (Bio-Rad).
Phosphorylation and flow cytometry assessment
To determine ERK1/2 phosphorylation, cells were suspended
in HBSS buffer containing 0.1% BSA, and stimulated with mouse
recombinant C5a (10 mM) at 37uC. Cells were lysed in ice-cold
buffer (100 mM Tris-HCL (pH 7.5), 5 mM EDTA, 50 mM NaCl,
5 mM EGTA, 1 mM Na3VO4, 50 mM NaF, 0.25% Na-
deoxycholic acid, 0.1% SDS, 1% Triton6100, 10 mg/ml protease
inhibitors). The antibodies to detect ERK1/2 or pERK1/2 were
from Santa Cruz. To determine anaphylatoxin receptor (CD88
and C5L2) cell surface expression, peripheral blood leukocytes,
resuspended in HBSS buffer containing 0.1% BSA and stimulated
with LPS (1 mg/ml) at 37uC. For flow cytometry, cells were stained
in triplicates with anti Gr1 (Pharmingen), anti F4/80 (eBioscience),
anti-C5L2 (HyCult biotechnology) or anti-CD88 antibodies
(Cedarlane laboratories). To determine the total C5L2 protein
expression, cells were permeabilized by using Cytofix/Cytoperm
(BD Pharmingen) and stained according to the manufacturers’
instructions. Stained cells were analyzed on a LSR flow cytometer
(Becton Dickinson). The % of receptor up- or down-regulation was
determined as described [45].
Supporting Information
Figure S1 Anaphylatoxin C5a-ELISA standard curve.
The standard curve was generated using mouse recombinant C5a
as standard and Abs reactive to mouse C5a to capture and detect
C5a. Measurements, in triplicate, 6 s.d., are shown.
(TIF)
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